MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
0.7260
+0.0150
+2.11%
Opening 13:15 05/28 EDT
OPEN
0.7400
PREV CLOSE
0.7110
HIGH
0.7400
LOW
0.7112
VOLUME
50.68K
TURNOVER
0
52 WEEK HIGH
80.96
52 WEEK LOW
0.6700
MARKET CAP
2.96M
P/E (TTM)
-0.0074
1D
5D
1M
3M
1Y
5Y
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
NASDAQ · 5h ago
Weekly Report: what happened at APVO last week (0520-0524)?
Weekly Report · 1d ago
Aptevo Therapeutics Has Been Granted Canadian Patent Number 2999138 Titled "CD3 BINDING POLYPEPTIDES (FOR THE TREATMENT OF CANCER)"
Benzinga · 6d ago
Weekly Report: what happened at APVO last week (0513-0517)?
Weekly Report · 05/20 10:12
Weekly Report: what happened at APVO last week (0506-0510)?
Weekly Report · 05/13 10:17
Aptevo Therapeutics Inc. Quarterly Report on Form 10-Q
Press release · 05/09 03:18
APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024
Aptevo Therapeutics reported earnings per share of -$9.95 for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for -$12.84. Apteva Therapeutic reported results for the second quarter of 2016.
Investorplace · 05/08 16:54
Weekly Report: what happened at APVO last week (0429-0503)?
Weekly Report · 05/06 10:22
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.